Calidi Biotherapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Calidi Biotherapeutics, Inc. (CLDI) reported Increase (Decrease) in Prepaid Expense and Other Assets of $327.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $261.00K.
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $66.00K, a 79.18% decline year-over-year.
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $4.00K, a 98.39% decline year-over-year.
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$118.00K.
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $42.00K.
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$1.80M, a 181.16% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $2.22M.
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$170.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $261.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $327.00K 10-Q · filed 2026-08-13 | $331.00K derived: sum of 3 quarters · filed 2026-08-13 | $213.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $66.00K 10-Q · filed 2026-05-14 | $70.00K derived: sum of 2 quarters · filed 2026-05-14 | -$48.00K derived: sum of 3 quarters · filed 2026-05-14 | -$209.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$114.00K derived: sum of 2 quarters · filed 2026-03-27 | -$275.00K derived: sum of 3 quarters · filed 2026-08-13 | $42.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | -$118.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$279.00K derived: sum of 2 quarters · filed 2026-08-13 | $38.00K 10-Q · filed 2025-11-13 | $287.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$161.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $156.00K 10-Q · filed 2026-08-13 | $405.00K derived: sum of 3 quarters · filed 2026-08-13 | -$63.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $317.00K 10-Q · filed 2026-05-14 | $566.00K derived: sum of 2 quarters · filed 2026-05-14 | $98.00K derived: sum of 3 quarters · filed 2026-05-14 | $91.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$219.00K derived: sum of 2 quarters · filed 2026-03-27 | -$226.00K derived: sum of 3 quarters · filed 2026-03-27 | -$1.80M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$468.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$475.00K derived: sum of 2 quarters · filed 2025-11-13 | -$2.05M 10-Q · filed 2025-11-13 | -$1.70M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$1.58M 10-Q · filed 2025-08-08 | -$1.23M derived: sum of 3 quarters · filed 2025-08-08 | $72.00K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$1.57M 10-Q · filed 2025-05-14 | -$1.22M derived: sum of 2 quarters · filed 2025-05-14 | $79.00K derived: sum of 3 quarters · filed 2025-05-14 | $361.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $352.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.65M derived: sum of 2 quarters · filed 2025-03-31 | $1.94M derived: sum of 3 quarters · filed 2025-03-31 | $2.22M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.58M derived: sum of 2 quarters · filed 2024-11-12 | $1.87M 10-Q · filed 2024-11-12 | $2.02M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $282.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $565.00K 10-Q · filed 2024-08-13 | $713.00K derived: sum of 3 quarters · filed 2024-08-13 | |
| 2023-03-31 | $283.00K 10-Q · filed 2024-05-14 | $431.00K derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$170.00K 10-K · filed 2024-03-15 | ||
| 2022-09-30 | -$318.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |